Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives

Heitmann, Jonas S. and Pfluegler, Martin and Jung, Gundram and Salih, Helmut R. (2021) Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers, 13 (3). p. 549. ISSN 2072-6694

[thumbnail of cancers-13-00549.pdf] Text
cancers-13-00549.pdf - Published Version

Download (1MB)

Abstract

Prostate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a cornerstone for treatment of other malignancies is established in PC. This refers to immune checkpoint inhibition (CI), which generally reinforces T cell immunity as well as chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) that stimulate the T cell receptor/CD3-complex and mobilize T cells in a targeted manner. In general, compared to CAR-T cells, bsAb would have the advantage of being an “off the shelf” reagent associated with less preparative effort, but at present, despite enormous efforts, neither CAR-T cells nor bsAbs are successful in solid tumors. Here, we focus on the various bispecific constructs that are presently in development for treatment of PC, and discuss underlying concepts and the state of clinical evaluation as well as future perspectives.

Item Type: Article
Subjects: West Bengal Archive > Medical Science
Depositing User: Unnamed user with email support@westbengalarchive.com
Date Deposited: 25 Jan 2023 10:54
Last Modified: 25 May 2024 09:14
URI: http://article.stmacademicwriting.com/id/eprint/22

Actions (login required)

View Item
View Item